Immune Response of Recombinant Pseudorabies Virus rPRV-VP2 Expressing VP2 Gene of Porcine Parvovirus in Mice.
- Author:
Pengfei FU
;
Xinlong PAN
;
Qiao HAN
;
Xingwu YANG
;
Qianlei ZHU
;
Xiaoqing GUO
;
Yu ZHANG
;
Hongying CHEN
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies, Viral;
immunology;
Antigens, Viral;
administration & dosage;
genetics;
immunology;
Capsid Proteins;
administration & dosage;
genetics;
immunology;
Female;
Gene Expression;
Genetic Vectors;
genetics;
metabolism;
Herpesvirus 1, Suid;
genetics;
metabolism;
Mice;
Parvovirus, Porcine;
genetics;
immunology;
Swine;
Swine Diseases;
immunology;
prevention & control;
virology;
Viral Vaccines;
administration & dosage;
genetics;
immunology
- From:
Chinese Journal of Virology
2016;32(2):195-202
- CountryChina
- Language:Chinese
-
Abstract:
In order to develop a combined live vaccine that will be used to prevent against porcine parvovirus (PPV) and Pseudorabies virus (PRV) infection, the VP2 gene of PPV was inserted into the transfer vector plasmid pG to produce the recombinant plasmid pGVP2. The plasmid pGVP2 and the genome of PRV HB98 attenuated vaccine were transfected by using lipofectamine into swine testis cells for the homologous recombination. The recombinant virus rPRV-VP2 was purified by selection of green fluorescence plaques for five cycles. 6-week-old female Kunming mice were immunized intramuscularly with attenuated PRV parent HB98 strain, commercial inactivated vaccine against PPV, recombinant virus, DMEM culture solution. The injections were repeated with an equivalent dose after 2 weeks in all of the groups, and then challenged with the virulent PRV NY strain at 7 weeks after the first immunization. The recombinant virus rPRV-VP2 was successfully generated, and the recombinant virus could effectively elicite anti-PPV and PRV antibody and significant cellular immune response as indicated by anti-PPV ELISA and HI, PRV-neutralizing assay and flow cytometry. The challenge assay indicated that recombinant virus could protect the mice against the virulent PRV challenge. These results demonstrated that the recombinant virus can be a candidate recombinant vaccine strain for the prevention of PRV and PPV.
